US20110300603A1 - Tagged Ligands for Enrichment of Rare Analytes from a Mixed Sample - Google Patents

Tagged Ligands for Enrichment of Rare Analytes from a Mixed Sample Download PDF

Info

Publication number
US20110300603A1
US20110300603A1 US13/182,003 US201113182003A US2011300603A1 US 20110300603 A1 US20110300603 A1 US 20110300603A1 US 201113182003 A US201113182003 A US 201113182003A US 2011300603 A1 US2011300603 A1 US 2011300603A1
Authority
US
United States
Prior art keywords
ligand
atl
cells
affinity tag
affinity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/182,003
Inventor
Allyn Forsyth
Helen Barnes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
On Q ity
Original Assignee
On Q ity
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by On Q ity filed Critical On Q ity
Priority to US13/182,003 priority Critical patent/US20110300603A1/en
Publication of US20110300603A1 publication Critical patent/US20110300603A1/en
Priority to US13/692,710 priority patent/US20130260392A1/en
Priority to US14/103,352 priority patent/US20140234986A1/en
Priority to US14/995,894 priority patent/US10359429B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502761Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip specially adapted for handling suspended solids or molecules independently from the bulk fluid flow, e.g. for trapping or sorting beads, for physically stretching molecules
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00Sampling; Preparing specimens for investigation
    • G01N1/28Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40Concentrating samples
    • G01N1/405Concentrating samples by adsorption or absorption
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326Magnetic particles
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/06Fluid handling related problems
    • B01L2200/0647Handling flowable solids, e.g. microscopic beads, cells, particles
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00Additional constructional details
    • B01L2300/08Geometry, shape and general structure
    • B01L2300/0861Configuration of multiple channels and/or chambers in a single devices
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00Moving or stopping fluids
    • B01L2400/08Regulating or influencing the flow resistance
    • B01L2400/084Passive control of flow resistance
    • B01L2400/086Passive control of flow resistance using baffles or other fixed flow obstructions
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/971Capture of complex after antigen-antibody reaction
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/973Simultaneous determination of more than one analyte
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/10Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/101666Particle count or volume standard or control [e.g., platelet count standards, etc.]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/13Tracers or tags
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/25Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25125Digestion or removing interfering materials
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/25Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25375Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]

Definitions

  • CD4 T cell levels can reflect the course of disease in AIDS patients
  • cellular lymphoid and myeloid markers can aid leukemia and lymphoma diagnoses
  • the presence of errant epithelial cells in the blood may signify a metastasizing cancer.
  • FACS fluorescent activated cell sorting
  • Another popular method of cell separation involves magnetically labeling a target population of cells, e.g. with ferromagnetic beads, followed by sorting the labeled cells by passing them through a receptacle positioned within a magnetic field, a process also known as magnetic activated cell sorting (MACS).
  • MACS magnetic activated cell sorting
  • methods for enriching specific cells in a cellular sample comprise a method for enriching rare cells from a cellular sample comprising contacting in solution a cellular sample with affinity-tagged ligands (ATLs) each comprising a first ligand linked to an affinity tag, wherein the ligand selectively binds a cellular marker of the rare cells and the affinity tag can be selectively captured by a capture moiety, wherein the affinity tags do not comprise a magnetic particle; and flowing the sample through a microfluidic device comprising the capture moiety to selectively retain ATL-bound cells.
  • ATLs affinity-tagged ligands
  • the method comprises a method for enriching rare cells from a cellular sample comprising: contacting in solution the cellular sample with affinity-tagged ligands (ATLs) each comprising:
  • a ligand linked to a plurality of affinity tags wherein the ligand selectively binds a cellular marker of the rare cells and the affinity tag can be selectively captured by a capture moiety and wherein the ratio of ligand:affinity tag of the ATL's is less than 1:1; flowing the sample through a microfluidic device comprising the capture moiety to selectively retain ATL-bound cells.
  • methods for enriching specific cells in a cellular sample comprise a method for enriching rare cells, wherein the rare cells are circulating tumor cells or epithelial cells, from a cellular sample comprising contacting in solution a cellular sample with affinity-tagged ligands (ATLs) each comprising a first ligand linked to an affinity tag, wherein the ligand is folic acid, Dolichos Biflorus Agglutinin (DBA), epidermal growth factor (EGF), EGF peptide (amino acid sequence YHWYGYTPQNVI), epi peptide (amino acid sequence QMARIPKRLARH), transforming growth factor-alpha (TGF-alpha), Urokinase Plasminogen Activator (UPA), FasL, MUC1/sec, catenin, ICAM-1, plasminogen, or the like and selectively binds a cellular marker of the rare cells and the affinity tag can be selectively captured by a
  • ATLs affinity-tagged
  • the method comprises a method for enriching rare cells from a cellular sample comprising: contacting in solution the cellular sample with affinity-tagged ligands (ATLs) each comprising:
  • a ligand linked to a plurality of affinity tags wherein the ligand is folic acid or epidermal growth factor (EGF) and selectively binds a cellular marker of the rare cells wherein the rare cells are circulating tumor cells or epithelial cells, and the affinity tag and wherein the ratio of ligand:affinity tag of the ATL's is less than 1:1; flowing the sample through a microfluidic device comprising the capture moiety to selectively retain ATL-bound cells.
  • EGF epidermal growth factor
  • methods for enriching specific cells in a cellular sample comprise a method for enriching rare cells, wherein the rare cells are circulating tumor cells or epithelial cells, from a cellular sample comprising contacting in solution a cellular sample with affinity-tagged ligands (ATLs) each comprising a first ligand linked to an affinity tag, wherein the ligand is an antibody that is anti-EpCam; anti-E-Cadherin, anti-Mucin-1, anti-Cytokeratin (CK) 8, anti-epidermal growth factor receptor (EGFR), anti-cytokeratin (CK)19, anti-ErbB2, anti-PDGF, anti-L6, or anti-leukocyte associated receptor (LAR) and selectively binds a cellular marker of the rare cells and the affinity tag can be selectively captured by a capture moiety, wherein the affinity tags comprise biotin, desthiobiotin, histidine, polyhistidine, myc, hemagglut
  • the method comprises a method for enriching rare cells from a cellular sample comprising: contacting in solution the cellular sample with affinity-tagged ligands (ATLs) each comprising:
  • a ligand linked to a plurality of affinity tags wherein the ligand is an antibody that is anti-EpCam; anti-E-Cadherin, anti-Mucin-1, anti-Cytokeratin (CK) 8, anti-epidermal growth factor receptor (EGFR), anti-cytokeratin (CK)19, anti-ErbB2, anti-PDGF, anti-L6, or anti-leukocyte associated receptor (LAR) and selectively binds a cellular marker of the rare cells wherein the rare cells are circulating tumor cells or epithelial cells, and the affinity tag and wherein the ratio of ligand:affinity tag of the ATL's is less than 1:1; flowing the sample through a microfluidic device comprising the capture moiety to selectively retain ATL-bound cells.
  • the method comprises a method for enriching rare analytes from a sample comprising:
  • ATLs affinity-tagged ligands
  • said mixture of ATL's comprises: a first ATL comprising a first ligand that selectively binds a first marker of rare analytes, wherein the first ligand is linked to a first affinity tag that is selectively captured by a first capture moiety; and a second ATL comprising a second ligand that selectively binds a second marker of rare analytes, wherein said second ligand is linked to a second affinity tag, wherein the second affinity tag is selectively captured by the first capture moiety; and contacting the sample with the capture moiety to selectively enrich the rare analytes.
  • the method comprises a method for enriching rare analytes from a sample comprising:
  • ATLs affinity-tagged ligands
  • said mixture of ATL's comprises: a first ATL comprising a first ligand that selectively binds a first marker of rare analytes, wherein the first ligand is linked to a first affinity tag that is selectively captured by a first capture moiety; and a second ATL comprising a second ligand that selectively binds a second marker of rare analytes, wherein said second ligand is linked to a second affinity tag, wherein the second affinity tag is selectively captured by the first capture moiety; contacting the sample with the capture moiety to selectively enrich the rare analytes; wherein the first affinity tag and said second affinity tag are identical; and wherein the ligand is folic acid, (DBA), EGF; EGF peptide (amino acid sequence YHWYGYTPQNVI), epi peptide (amino acid sequence QMARIPKRLARH), TGF-
  • the method comprises a method for enriching rare analytes such as cells from a sample such as a blood sample comprising: contacting in solution said sample with a plurality of affinity-tagged ligands (ATLs) wherein said mixture of ATL's comprises: a first ATL comprising a first ligand that selectively binds a first marker of rare analytes, wherein the first ligand is linked to a first affinity tag that is selectively captured by a first capture moiety; and a second ATL comprising a second ligand that selectively binds a second marker of rare analytes, wherein said second ligand is linked to a second affinity tag, wherein the second affinity tag is selectively captured by the first capture moiety; contacting the sample with the capture moiety to selectively enrich the rare analytes; wherein the mixture of ATL's comprises at least 3, 4, 5, 6, 7, 8, 9, or 10 ATL's each of which comprises an affinity tag that can be selectively captured by the first capture mo
  • the method comprises a method for enriching rare analytes such as cells from a sample such as a blood sample comprising: contacting in solution said sample with a plurality of affinity-tagged ligands (ATLs) wherein said mixture of ATL's comprises: a first ATL comprising a first ligand that selectively binds a first marker of rare analytes, wherein the first ligand is linked to a first affinity tag that is selectively captured by a first capture moiety; and a second ATL comprising a second ligand that selectively binds a second marker of rare analytes, wherein said second ligand is linked to a second affinity tag, wherein the second affinity tag is selectively captured by the first capture moiety; contacting the sample with the capture moiety to selectively enrich the rare analytes; wherein the mixture of ATL's comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 ATL's each of which comprises an affinity tag that can be selectively captured by the first
  • the method comprises a method of diagnosing a condition such as cancer in a patient comprising: enriching rare cells from the patient through any of the methods described herein; and evaluating, identifying, or quantitating the ATL bound cells.
  • the invention comprises a reagent comprising a plurality of affinity tagged ligands each of which comprises a ligand that selectively binds a different cancer cellular marker linked to an identical affinity tag that is selectively captured by a capture moiety wherein the ratio of ligand:affinity tag per ATL is less than 1:1; wherein the reagent comprises at least 1, 2, 3, 4, or 5 different ATL's.
  • the device comprises a microfluidic device comprising an array of obstacles, wherein the obstacles are functionalized with capture moieties comprising EGF-peptide, EPI-peptide, folate or DBA.
  • FIG. 1A is a fluorescent image illustrating the capture of lung cancer cells with a non-specific affinity tagged ligand (biotinylated anti-IgG).
  • FIG. 1B is a fluorescent image illustrating the capture of lung cancer cells with biotinylated anti-EpCam antibody, an antibody that is specific for an epithelial cell marker present on lung cancer cells.
  • FIG. 2A is a diagram illustrating the capture of cells with a ligand tagged with an affinity tag such as biotin, histidine, or a magnetic particle (top panel), and the affinity-based capture of such cells using a microfluidic chip coated with a capture moiety capable of interacting with the affinity tag (bottom panel).
  • an affinity tag such as biotin, histidine, or a magnetic particle
  • FIG. 2B is a fluorescent image illustrating the capture of cells bound to Biotin-tagged EGF using a microfluidic device coated with Avidin, a capture moiety capable of interacting with the affinity tag.
  • FIG. 3 is a Table of exemplary markers contemplated herein.
  • the present disclosure provides compositions, methods and devices for the detection and isolation of rare analytes from a mixed sample.
  • Rare analytes include cells and particles, such as eukaryotic cells, prokaryotic cells, cellular organelles, cellular fragments, viruses, nucleic acids, proteins, and protein complexes.
  • a mixed sample may include a fluid sample, e.g., water, air, bodily fluids such as blood, urine, etc.
  • a mixed sample may also include a solid sample that is liquefied, e.g., a tumor biopsy, food solids, etc.
  • An ATL may comprise Formula I:
  • L is a ligand that selectively binds a marker for a rare analyte
  • x is the number of ligands within each ATL
  • AT is an affinity tag which can be selectively captured using a capture moiety
  • n is the number of ATs linked to the ligand.
  • L and AT may be linked together directly or indirectly (via a linker).
  • Linkers may be straight or branched.
  • a linker may be a peptide, polypeptide, protein, and the like.
  • the linker moiety is a branched polymer.
  • Such branched polymers include modified dextran, polyethylene glycol, polypropylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, polyethylene acrylamide and combinations thereof.
  • the linker is branched and comprises multiple ATs.
  • an ATL comprises at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100 or more ATs per L.
  • the AT's can each be linked to the ligand via a single linker or via a plurality of linkers (e.g., one linker per AT).
  • ligands contemplated in the methods herein include ligands that selectively bind cell surface marker(s) (e.g., receptors and adhesion molecules) of rare cells of interest.
  • a ligand can comprise molecule(s), peptide(s), polypeptides, particles, and the like, and/or fragments thereof.
  • the ligand can be naturally occurring or artificially synthesized.
  • Rare cells include circulating tumor cells (CTCs), circulating epithelial cells or circulating stem cells.
  • a ligand comprises an antibody, such as a monoclonal antibody or a polyclonal antibody.
  • ligand antibodies contemplated herein include antibodies that selectively bind CTCs, circulating epithelial cells, or circulating stem cells.
  • such antibodies selectively bind an antigen such as EpCam; E-Cadherin, Mucin-1, Cytokeratin (CK) 8, epidermal growth factor receptor (EGFR), cytokeratin (CK)19, ErbB2, PDGF, L6, or leukocyte associated receptor (LAR).
  • the ligand may be an antibody to a marker listed in FIG. 3 .
  • a ligand is not an antibody.
  • non-antibody ligands include folic acid, Dolichos Biflorus Agglutinin (DBA), epidermal growth factor (EGF), EGF peptide (amino acid sequence YHWYGYTPQNVI), epi peptide (amino acid sequence QMARIPKRLARH), transforming growth factor-alpha (TGF-alpha), Urokinase Plasminogen Activator (UPA), FasL, MUC1/sec, catenin, ICAM-1, plasminogen, or the like.
  • the ligand activates a cellular process, and in other embodiments, the ligand may not activate a cellular process.
  • An ATL may have a single ligand or multiple ligands (e.g., x>1, or x>2, 5, 10, 20, or more).
  • each ligand may be identical to the other ligands, different from the other ligands, or a combination thereof.
  • Affinity tags can include molecules, peptides, polypeptides, particles, and/or other substances capable of being captured by a capture moiety or enrichment device.
  • ATs include biotin, desthiobiotin, histidine, poly-histidine, glutathione S transferase (GST), myc, hemagglutinin (HA), FLAG, fluorescence tag, tandem affinity purification (TAP) tags, or derivatives thereof.
  • the TAP tag may comprise calmodulin-binding protein, TEV, and protein A or G subunit.
  • the affinity tag comprises a magnetic particle.
  • the affinity tag is a molecule or particle other than a magnetic particle.
  • an affinity tag does not comprise an antibody.
  • an ATL may comprise one AT, or, for example, may comprise at least 2, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or more ATs.
  • the sample is mixed with a homogenous or heterogeneous set of ATLs.
  • the sample is incubated with the ATLs for a sufficient amount of time to enable binding of the ligands to the receptors or rare analytes.
  • the sample and ATLs are then applied to one or more capture moieties that selectively bind the affinity tags, thereby allowing enrichment of the bound rare analytes.
  • the capture moiety can be coupled to a solid support (e.g. a tube, a flat substrate, or an array of obstacles).
  • the sample is first solubilized and then mixed with the mixture of ATLs as described above. Once the sample is incubated with the ATLs for a sufficient period of time to allow binding between the ligands and the rare analyte markers, the sample is applied to one or more capture moieties that selectively binds to the affinity tag.
  • Capture moieties may be inorganic molecules, organic molecules, peptides, polypeptides, and/or antibodies, and the like, or may include fragments of, or derivatives, of same.
  • the capture moieties are capable of binding to, or interacting with, an affinity tag.
  • Examples of capture moieties include, but are not limited to, a magnet or magnetized substrate, avidin, streptavidin, NeutravidinTM, glutathione, nickel, calcium/calmodulin, or IgG.
  • Other examples of capture moieties include magnetic or magnetized surfaces, avidin and avidin-coated particles.
  • capture moieties are part of a microfluidic device (e.g., a microfluidic gap or channel coated with capture moieties).
  • a microfluidic device contemplated herein can comprise an array of obstacles that form a network of microfluidic channels.
  • the affinity tags can bind irreversibly or reversibly to the capture moiety(ies).
  • an affinity tag may be releasable from the capture moiety.
  • desthio-biotin may be used as an affinity tag with avidin as the capture moiety. The bond between biotin and avidin can then be released by applying desphio-biotin or biotin to the sample.
  • the ATL's herein can be used to enrich rare analytes such as cells from a mixed sample such as blood.
  • Such method comprises the step of contacting in solution a test sample with affinity-tagged ligands (ATLs).
  • ATLs affinity-tagged ligands
  • Each ATL comprises: at least one ligand linked to at least one affinity tag.
  • the ligand and affinity tag are optionally liked via a linker comprising one or more of modified dextran, polyethylene glycol, polypropylene glycol, polyvinyl alcohol, or polyvinylpyrrolidone.
  • the ligands of the ATL's selectively bind a one or more markers of the rare analytes.
  • the affinity tags of the ATLs are ones that can be selectively captured by a single capture moiety or a plurality of capture moieties. Examples of capture moieties contemplated for any of the embodiments herein include avidin, streptavidin, NeutravidinTM, nickel, or glutathione.
  • the affinity tags may be one that does not comprise a magnetic particle.
  • affinity tags include biotin, desthiobiotin, histidine, polyhistidine, myc, hemagglutinin (HA), FLAG, fluorescence tag, tandem affinity purification (TAP) tags, FLAG, glutathione S transferase (GST) or derivatives thereof.
  • each ATL comprises a ratio of ligand to affinity tag such that there are more affinity tags for each ligand.
  • the ligand:affinity tag ratio is less than 1:1 or less than 1:5 or less than 1:10 or less than 1:100.
  • a single ATL can have at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 different ligands.
  • Each of the ligands can be specific to a different marker, such as a cancer marker.
  • Cellular cancer markers contemplated herein include markers for a cancer such as breast, prostate, liver, ovary, skin, colon, rectum, cervix, esophagus, stomach, brain, lung, pancreatic, or endometrium cancer.
  • a cellular marker is epidermal growth factor receptor (EGFR), EPCAM, or folic acid receptor.
  • the cellular marker is E-Cadherin, Mucin-1, Cytokeratin (CK) 8, cytokeratin (CK)19, ErbB2, PDGF, L6, or leukocyte associated receptor (LAR) In other instances it is any marker listed in the table of FIG. 3 .
  • the ligands in the ATL's can be one or more of the following: folic acid, epidermal growth factor (EGF), transforming growth factor-alpha (TGF-alpha), Urokinase Plasminogen Activator (UPA), FasL, MUC1/sec, catenin, ICAM-1, plasminogen, or fragments thereof.
  • the ligands comprise haptens.
  • the ligand is an antibody and in others it is not an antibody.
  • a reagent used to enrich/detect rare analytes comprises a plurality of affinity-tagged ligands (ATLs) wherein each ATL comprises: a first ATL comprising a first ligand that selectively binds a first marker of the rare analytes linked to a first affinity tag that is selectively captured by a first capture moiety; and a second ATL comprising a second ligand that selectively binds a second marker linked to a second affinity tag, wherein the second affinity tag is selectively captured by the first capture moiety.
  • the reagent described above is mixed with a mixed sample of analytes.
  • the sample/ATL mixture is contacted with the first capture moiety to selectively enrich the rare analytes.
  • the capture moiety can be avidin and the capture moiety can be in a microfluidic gap or channel.
  • the first and second affinity tags can be identical (both biotin) or different (biotin and desphio-biotin) but both selectively captured by the same capture moiety.
  • a mixed sample such as the one described above is contacted with at least 3, 4, 5, 6, 7, 8, 9, or 10 different ATL's each of which comprises an affinity tag that can be selectively captured by a single capture moiety or the same affinity tag.
  • a sample such as a blood sample
  • ATLs of similar configuration may be contacted with the targeted analytes.
  • a mixture of different ATLs may be used.
  • step-wise purification of the analyte may occur through sequential use of the same or different ATLs.
  • An exemplary ATL can have a single ligand comprising anti-EpCAM antibody linked to a plurality of ATs, each of which comprises a biotin molecule.
  • the ATs are linked to the ligand via a branched linker such that each ligand is coupled to at least five ATs.
  • the ligand may bind the marker (EpCAM) at more than one site. In other embodiments, e.g., EGF, the ligand binds the marker only once.
  • the sample flows through a microfluidic device, optionally comprising an array of obstacles, coated with avidin capture moieties. Enriched rare cells (e.g., circulating epithelial cells) can then be visualized/detected using any means known in the art, including fluorescent in situ hybridization (FISH) staining.
  • FISH fluorescent in situ hybridization
  • the ATLs may be conjugated to one or more detectable labels.
  • detectable labels comprise fluorescent markers, HRP-alkaline phosphatase detection or quantum dots.
  • the cells in addition to an ATL, the cells may be contacted with a detectably-labeled ligand specific for a cellular marker.
  • detectable labels may comprise one or more of fluorescent probes, magnetic particles, or quantum dots.
  • the detectably-labeled ligands comprise the ligands described herein relating to ATLs.
  • An example of a detectably-labeled ligand is a fluorescently-labeled antibody.
  • Varying the number of affinity tags and/or ligands in a single ATL may affect the ability to capture target analytes.
  • the disclosure provides ATLs with more than one affinity tag and/or more than one ligand.
  • the affinity tags may be identical tags, similar tags, or different tags. Since higher affinity-tag-to-ligand ratios may result in enhanced or more efficient capture of cells, the ratio of affinity tag to ligand in a single ATL may be greater than or equal to 1, for example, 2:1, 3:1, 4:1, 5:1, 10:1, 20:1, or greater.
  • the marker is a marker for one or more of the following: cancer of the breast, lung, prostate, liver, ovary, skin, colon, rectum, cervix, esophagus, stomach, brain, bladder, kidney, testicular, or endometrium.
  • the marker is for a blood cancer such as leukemia or lymphoma.
  • vascular disease is monitored by enriching for cells with endothelial markers.
  • Other cancers may also be monitored by enriching for endothelial cells.
  • fetal markers e.g. Y chromosome proteins, gamma globin
  • stem cell markers CD44 are used to capture stem cells.
  • the methods provided comprise contacting a cellular sample with one or more ATLs to enable binding to one or more cellular markers, followed by capture of the bound cells by an enrichment device.
  • the contacting of the cellular sample with one or more ATLs may occur under conditions pre-determined to maximize binding efficiency.
  • the conditions may be optimized to minimize non-specific binding.
  • the timing of the contacting between the cellular sample and the one or more ATLs may be optimized.
  • Such optimized or predetermined amount of time may be used for the contacting step.
  • conditions for the temperature of the contacting step may be optimized to maximize binding efficiency and/or to minimize internalization of cellular markers.
  • a pre-determined or optimized temperature or temperatures may be used for the contacting step.
  • the composition of the solution containing the cellular sample and/or the ATL may be optimized for more efficient binding.
  • Blocking reagents or serums may be added to aid in binding efficiency. Examples of such blocking reagents include bovine serum albumin (BSA), fetal calf serum (FCS), milk, and other commercially-obtainable reagents.
  • BSA bovine serum albumin
  • FCS fetal calf serum
  • milk and other commercially-obtainable reagents.
  • the methods may further comprise a wash step in which unbound (or free) ATL is removed from the cellular sample prior to capture by the enrichment device.
  • the wash step could be accomplished by one or more rounds comprising centrifugation of the cellular sample, aspiration of the supernatant, and re-suspension of the cellular sample in wash buffer.
  • the composition of the wash buffer may comprise buffered solutions and may be optimized to maximize binding efficiency.
  • the optimized wash buffer may comprise one or more blocking reagents or serums described herein.
  • the cells are added to an enrichment device that comprises a surface functionalized with a capture moiety recognizing the affinity tag or a cellular marker, such as a receptor.
  • a surface of the enrichment device is coated or treated with one or more capture moieties (e.g., avidin or Neutravidin) in order to allow capture of the ATL-bound cells.
  • capture moieties e.g., avidin or Neutravidin
  • capture-moieties are not antibodies.
  • capture moieties are ligands.
  • the enrichment device comprises a surface coated or functionalized with a ligand that is used to directly enrich cells expressing a specific marker from a mixed cell population.
  • the surface of such enrichment device is functionalized with folate in order to enrich cells expressing the folate receptor.
  • the enrichment device is functionalized with Dolichos Biflorus Agglutinin (DBA), epidermal growth factor (EGF), EGF peptide (amino acid sequence YHWYGYTPQNVI), epi peptide (amino acid sequence QMARIPKRLARH), transforming growth factor-alpha (TGF-alpha), Urokinase Plasminogen Activator (UPA), FasL, MUC1/sec, catenin, ICAM-1, plasminogen, or the like. Parameters such as timing, temperature, and/or buffer composition may be optimized to promote optimal capture by the enrichment device.
  • the enrichment device may include one or more arrays of obstacles that allow lateral displacement of cells and other components of fluids.
  • Such arrays of obstacles comprise different configurations.
  • a row or rows of obstacles are arranged with a 50% offset from other randomly- or non-randomly-arranged obstacles creating restricted and expanded gaps.
  • the obstacles within the array of obstacles are coated or treated with one or more capture moieties or ligands.
  • the enrichment device is capable of sorting cells based on another variable, e.g. hydrodynamic size, as well as capturing ATL-bound cells.
  • Enrichment devices include, but are not limited to centrifuge, microfuge and ultracentrifuge test tubes.
  • the enrichment device is a column or other such receptacle such as a magnetic activated cell sorting (MACS) column.
  • MCS magnetic activated cell sorting
  • any of the ATLs herein may be designed to enrich cancer cells as well as prognose and diagnose cancer conditions.
  • cancer can be staged or diagnosed by enriching rare cells (e.g., epithelial cells, circulating cancer stem cells) using ATL's by any of the means described above. Subsequently, the enriched cells can be further evaluated or quantified.
  • diagnosis or prognoses comprises comparing the percentage or quantity of epithelial cells in the blood of a test subject with that in the blood of a healthy control subject, a panel of healthy control subjects, known standard levels, or similar information obtained from the same patient at a different point in time.
  • the present disclosure provides a method for screening a combinatorial peptide library for peptide ligands capable of binding cell surface markers.
  • Such methods comprise contacting a sample of cancer cells with a combinatorial peptide library, wherein the peptides have been pre-labeled with one or more affinity tags, described herein; purifying out the cells selectively binding to candidate peptide ligands; and identifying the candidate ligands bound to the cells.
  • the purifying may comprise the lateral flow of the cellular sample through a device coated with capture moieties that selectively bind the ATs so as to permit capture of the ATL bound cells
  • the example depicted in FIG. 1 illustrates a method and device for isolating cancer cells.
  • the affinity-tagged ligand (ATL) in this example comprised biotin as the affinity tag.
  • the ligand was anti-Epithelial Cell Adhesion Molecule (EpCam) antibody which recognizes an epithelial cellular marker.
  • EpCam anti-Epithelial Cell Adhesion Molecule
  • H1650 lung cancer cells were incubated with biotinylated goat anti-EpCam antibody for 1 hour on ice ( FIG. 1B ). Approximately 1000 cells were input into each experiment. The left and right images represent replicate experiments.
  • As a negative control H1650 lung cancer cells were incubated with biotinylated goat IgG antibody under the same or similar conditions ( FIG. 1A ). Following the incubation, the cells were washed and run through an array of obstacles [comprising a restricted gap—Chip 7, please confirm] chip coated with NeutravidinTM
  • FIG. 2 illustrates the capture of cells labeled with an affinity tag before being subjected to a microfluidic device.
  • FIG. 2A is a diagram depicting a cell being contacted with an affinity-tagged ligand in solution (top panel) and the capture of such cell with a microfluidic device coated with a capture moiety capable of recognizing the affinity-tag (lower panel).
  • FIG. 2B illustrates the capture of cells bound to EGF peptide tagged with biotin.
  • MDA-MB-231 cells a breast cell line which expresses low levels of EpCam
  • the cells were then subjected to a chip coated with neutravidin, a capture moiety capable of recognizing the affinity tag. Following fixation, the captured cells were visualized by fluorescent microscopy. The results demonstrate significant capture of cells using this method.

Abstract

Method of enriching specific cells from cellular samples are disclosed, comprising contacting in solution a cellular sample with affinity-tagged ligands (ATLs) each comprising a first ligand linked to an affinity tag, wherein the ligand selectively binds a cellular marker of the rare cells and the affinity tag can be selectively captured by a capture moiety, wherein the affinity tags do not comprise a magnetic particle; and flowing the sample through a microfluidic device comprising the capture moiety to selectively retain ATL-bound cells. Methods for enriching circulating tumor cells, and devices for enriching specific cells from cellular samples are also disclosed.

Description

    CROSS-REFERENCE
  • This application is a divisional of U.S. application Ser. No. 12/037,077 filed Feb. 25, 2008, which application is incorporated herein by reference.
  • BACKGROUND OF THE INVENTION
  • Analysis of a complex mixture such as blood can be difficult but provides valuable information. For example, CD4 T cell levels can reflect the course of disease in AIDS patients, cellular lymphoid and myeloid markers can aid leukemia and lymphoma diagnoses, and the presence of errant epithelial cells in the blood may signify a metastasizing cancer.
  • Such complex mixtures can be analyzed by fluorescent activated cell sorting (FACS), a technology that can quantitate marked analytes and also separate them out from the mixtures. Another popular method of cell separation involves magnetically labeling a target population of cells, e.g. with ferromagnetic beads, followed by sorting the labeled cells by passing them through a receptacle positioned within a magnetic field, a process also known as magnetic activated cell sorting (MACS). Despite their widespread use, FACS and MACS technologies have disadvantages, for example, they require machinery that is expensive and difficult to maintain. FACS techology has the added disadvantage of having limited portability.
  • Given the heavy demand, new approaches and technologies for cell sorting are needed for medical diagnostics and other applications.
  • SUMMARY OF THE INVENTION
  • In one aspect, methods for enriching specific cells in a cellular sample are provided. The methods comprise a method for enriching rare cells from a cellular sample comprising contacting in solution a cellular sample with affinity-tagged ligands (ATLs) each comprising a first ligand linked to an affinity tag, wherein the ligand selectively binds a cellular marker of the rare cells and the affinity tag can be selectively captured by a capture moiety, wherein the affinity tags do not comprise a magnetic particle; and flowing the sample through a microfluidic device comprising the capture moiety to selectively retain ATL-bound cells.
  • In some embodiments, the method comprises a method for enriching rare cells from a cellular sample comprising: contacting in solution the cellular sample with affinity-tagged ligands (ATLs) each comprising:
  • a ligand linked to a plurality of affinity tags, wherein the ligand selectively binds a cellular marker of the rare cells and the affinity tag can be selectively captured by a capture moiety and wherein the ratio of ligand:affinity tag of the ATL's is less than 1:1; flowing the sample through a microfluidic device comprising the capture moiety to selectively retain ATL-bound cells.
  • In one aspect, methods for enriching specific cells in a cellular sample are provided. The methods comprise a method for enriching rare cells, wherein the rare cells are circulating tumor cells or epithelial cells, from a cellular sample comprising contacting in solution a cellular sample with affinity-tagged ligands (ATLs) each comprising a first ligand linked to an affinity tag, wherein the ligand is folic acid, Dolichos Biflorus Agglutinin (DBA), epidermal growth factor (EGF), EGF peptide (amino acid sequence YHWYGYTPQNVI), epi peptide (amino acid sequence QMARIPKRLARH), transforming growth factor-alpha (TGF-alpha), Urokinase Plasminogen Activator (UPA), FasL, MUC1/sec, catenin, ICAM-1, plasminogen, or the like and selectively binds a cellular marker of the rare cells and the affinity tag can be selectively captured by a capture moiety, wherein the affinity tags comprise biotin, desthiobiotin, histidine, polyhistidine, myc, hemagglutinin (HA), FLAG, fluorescence tag, tandem affinity purification (TAP) tags, FLAG, or glutathione S transferase (GST) or derivatives thereof; and flowing the sample through a microfluidic device comprising the capture moiety to selectively retain ATL-bound cells; wherein the capture moiety comprises avidin, streptavidin, Neutravidin™, nickel, or glutathione or other molecule capable of binding the affinity tag; and wherein the cellular marker is a cancer marker for one or more of breast, prostate, liver, ovary, skin, colon, rectum, cervix, esophagus, stomach, brain, lung, or endometrium cancer.
  • In some embodiments, the method comprises a method for enriching rare cells from a cellular sample comprising: contacting in solution the cellular sample with affinity-tagged ligands (ATLs) each comprising:
  • a ligand linked to a plurality of affinity tags, wherein the ligand is folic acid or epidermal growth factor (EGF) and selectively binds a cellular marker of the rare cells wherein the rare cells are circulating tumor cells or epithelial cells, and the affinity tag and wherein the ratio of ligand:affinity tag of the ATL's is less than 1:1; flowing the sample through a microfluidic device comprising the capture moiety to selectively retain ATL-bound cells.
  • In one aspect, methods for enriching specific cells in a cellular sample are provided. The methods comprise a method for enriching rare cells, wherein the rare cells are circulating tumor cells or epithelial cells, from a cellular sample comprising contacting in solution a cellular sample with affinity-tagged ligands (ATLs) each comprising a first ligand linked to an affinity tag, wherein the ligand is an antibody that is anti-EpCam; anti-E-Cadherin, anti-Mucin-1, anti-Cytokeratin (CK) 8, anti-epidermal growth factor receptor (EGFR), anti-cytokeratin (CK)19, anti-ErbB2, anti-PDGF, anti-L6, or anti-leukocyte associated receptor (LAR) and selectively binds a cellular marker of the rare cells and the affinity tag can be selectively captured by a capture moiety, wherein the affinity tags comprise biotin, desthiobiotin, histidine, polyhistidine, myc, hemagglutinin (HA), FLAG, fluorescence tag, tandem affinity purification (TAP) tags, FLAG, or glutathione S transferase (GST) or derivatives thereof; and flowing the sample through a microfluidic device comprising the capture moiety to selectively retain ATL-bound cells; wherein the capture moiety comprises avidin, streptavidin, Neutravidin™, nickel, or glutathione or other molecule capable of binding the affinity tag; and wherein the cellular marker is a cancer marker for one or more of breast, prostate, liver, ovary, skin, colon, rectum, cervix, esophagus, stomach, brain, lung, or endometrium cancer.
  • In some embodiments, the method comprises a method for enriching rare cells from a cellular sample comprising: contacting in solution the cellular sample with affinity-tagged ligands (ATLs) each comprising:
  • a ligand linked to a plurality of affinity tags, wherein the ligand is an antibody that is anti-EpCam; anti-E-Cadherin, anti-Mucin-1, anti-Cytokeratin (CK) 8, anti-epidermal growth factor receptor (EGFR), anti-cytokeratin (CK)19, anti-ErbB2, anti-PDGF, anti-L6, or anti-leukocyte associated receptor (LAR) and selectively binds a cellular marker of the rare cells wherein the rare cells are circulating tumor cells or epithelial cells, and the affinity tag and wherein the ratio of ligand:affinity tag of the ATL's is less than 1:1; flowing the sample through a microfluidic device comprising the capture moiety to selectively retain ATL-bound cells.
  • In some embodiments, the method comprises a method for enriching rare analytes from a sample comprising:
  • contacting in solution said sample with a plurality of affinity-tagged ligands (ATLs) wherein said mixture of ATL's comprises: a first ATL comprising a first ligand that selectively binds a first marker of rare analytes, wherein the first ligand is linked to a first affinity tag that is selectively captured by a first capture moiety; and a second ATL comprising a second ligand that selectively binds a second marker of rare analytes, wherein said second ligand is linked to a second affinity tag, wherein the second affinity tag is selectively captured by the first capture moiety; and contacting the sample with the capture moiety to selectively enrich the rare analytes.
  • In some embodiments, the method comprises a method for enriching rare analytes from a sample comprising:
  • contacting in solution said sample with a plurality of affinity-tagged ligands (ATLs) wherein said mixture of ATL's comprises: a first ATL comprising a first ligand that selectively binds a first marker of rare analytes, wherein the first ligand is linked to a first affinity tag that is selectively captured by a first capture moiety; and a second ATL comprising a second ligand that selectively binds a second marker of rare analytes, wherein said second ligand is linked to a second affinity tag, wherein the second affinity tag is selectively captured by the first capture moiety; contacting the sample with the capture moiety to selectively enrich the rare analytes; wherein the first affinity tag and said second affinity tag are identical; and wherein the ligand is folic acid, (DBA), EGF; EGF peptide (amino acid sequence YHWYGYTPQNVI), epi peptide (amino acid sequence QMARIPKRLARH), TGF-alpha; Urokinase Plasminogen Activator (UPA), FasL, MUC1/sec, catenin, ICAM-1, plasminogen, or the like, or wherein the ligand is an antibody that is anti-EpCam; anti-E-Cadherin, anti-Mucin-1, anti-Cytokeratin (CK) 8, anti-epidermal growth factor receptor (EGFR), anti-cytokeratin (CK)19, anti-ErbB2, anti-PDGF, anti-L6, or anti-leukocyte associated receptor (LAR).
  • In some embodiments, the method comprises a method for enriching rare analytes such as cells from a sample such as a blood sample comprising: contacting in solution said sample with a plurality of affinity-tagged ligands (ATLs) wherein said mixture of ATL's comprises: a first ATL comprising a first ligand that selectively binds a first marker of rare analytes, wherein the first ligand is linked to a first affinity tag that is selectively captured by a first capture moiety; and a second ATL comprising a second ligand that selectively binds a second marker of rare analytes, wherein said second ligand is linked to a second affinity tag, wherein the second affinity tag is selectively captured by the first capture moiety; contacting the sample with the capture moiety to selectively enrich the rare analytes; wherein the mixture of ATL's comprises at least 3, 4, 5, 6, 7, 8, 9, or 10 ATL's each of which comprises an affinity tag that can be selectively captured by the first capture moiety;
  • In some embodiments, the method comprises a method for enriching rare analytes such as cells from a sample such as a blood sample comprising: contacting in solution said sample with a plurality of affinity-tagged ligands (ATLs) wherein said mixture of ATL's comprises: a first ATL comprising a first ligand that selectively binds a first marker of rare analytes, wherein the first ligand is linked to a first affinity tag that is selectively captured by a first capture moiety; and a second ATL comprising a second ligand that selectively binds a second marker of rare analytes, wherein said second ligand is linked to a second affinity tag, wherein the second affinity tag is selectively captured by the first capture moiety; contacting the sample with the capture moiety to selectively enrich the rare analytes; wherein the mixture of ATL's comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 ATL's each of which comprises an affinity tag that can be selectively captured by the first capture moiety and wherein each of the ATL's comprises a ratio of Ligand:Affinity Tag that is less than 1:5; and wherein the capture moiety is in a microfluidic device such as a microfluidic device comprising an array of obstacles; wherein the first or second ligand is folic acid, (DBA), EGF; EGF peptide (amino acid sequence YHWYGYTPQNVI), epi peptide (amino acid sequence QMARIPKRLARH), TGF-alpha; Urokinase Plasminogen Activator (UPA), FasL, MUC1/sec, catenin, ICAM-1, plasminogen, or the like, or wherein the ligand is an antibody that is anti-EpCam; anti-E-Cadherin, anti-Mucin-1, anti-Cytokeratin (CK) 8, anti-epidermal growth factor receptor (EGFR), anti-cytokeratin (CK)19, anti-ErbB2, anti-PDGF, anti-L6, or anti-leukocyte associated receptor (LAR); and wherein the affinity tag comprises biotin, desthiobiotin, histidine, polyhistidine, myc, hemagglutinin (HA), FLAG, fluorescence tag, tandem affinity purification (TAP) tags, FLAG, or glutathione S transferase (GST) or derivatives thereof; wherein the ligand is linked to the affinity tag either directly or via a linker comprising modified dextran, polyethylene glycol, polypropylene glycol, polyvinyl alcohol, or polyvinylpyrrolidone; and wherein the capture moiety comprises avidin, streptavidin, Neutravidin™, nickel, or glutathione or other molecule capable of binding the affinity tag.
  • In some embodiments, the method comprises a method of diagnosing a condition such as cancer in a patient comprising: enriching rare cells from the patient through any of the methods described herein; and evaluating, identifying, or quantitating the ATL bound cells.
  • In some embodiments, the invention comprises a reagent comprising a plurality of affinity tagged ligands each of which comprises a ligand that selectively binds a different cancer cellular marker linked to an identical affinity tag that is selectively captured by a capture moiety wherein the ratio of ligand:affinity tag per ATL is less than 1:1; wherein the reagent comprises at least 1, 2, 3, 4, or 5 different ATL's.
  • In some embodiments, the device comprises a microfluidic device comprising an array of obstacles, wherein the obstacles are functionalized with capture moieties comprising EGF-peptide, EPI-peptide, folate or DBA.
  • INCORPORATION BY REFERENCE
  • All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, and patent application was specifically and individually indicated to be incorporated by reference.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1A is a fluorescent image illustrating the capture of lung cancer cells with a non-specific affinity tagged ligand (biotinylated anti-IgG).
  • FIG. 1B is a fluorescent image illustrating the capture of lung cancer cells with biotinylated anti-EpCam antibody, an antibody that is specific for an epithelial cell marker present on lung cancer cells.
  • FIG. 2A is a diagram illustrating the capture of cells with a ligand tagged with an affinity tag such as biotin, histidine, or a magnetic particle (top panel), and the affinity-based capture of such cells using a microfluidic chip coated with a capture moiety capable of interacting with the affinity tag (bottom panel).
  • FIG. 2B is a fluorescent image illustrating the capture of cells bound to Biotin-tagged EGF using a microfluidic device coated with Avidin, a capture moiety capable of interacting with the affinity tag.
  • FIG. 3 is a Table of exemplary markers contemplated herein.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The present disclosure provides compositions, methods and devices for the detection and isolation of rare analytes from a mixed sample. Rare analytes include cells and particles, such as eukaryotic cells, prokaryotic cells, cellular organelles, cellular fragments, viruses, nucleic acids, proteins, and protein complexes. A mixed sample may include a fluid sample, e.g., water, air, bodily fluids such as blood, urine, etc. A mixed sample may also include a solid sample that is liquefied, e.g., a tumor biopsy, food solids, etc.
  • Enrichment, detection, and isolation of rare analytes is accomplished using affinity-tagged ligands (ATLs). An ATL may comprise Formula I:

  • Lx-ATn,  (Formula I)
  • wherein:
    L is a ligand that selectively binds a marker for a rare analyte;
    x is the number of ligands within each ATL;
    AT is an affinity tag which can be selectively captured using a capture moiety; and
    n is the number of ATs linked to the ligand.
  • L and AT may be linked together directly or indirectly (via a linker). Linkers may be straight or branched. A linker may be a peptide, polypeptide, protein, and the like. In some embodiments, the linker moiety is a branched polymer. Such branched polymers include modified dextran, polyethylene glycol, polypropylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, polyethylene acrylamide and combinations thereof. In some embodiments, the linker is branched and comprises multiple ATs. For example, in some embodiments an ATL comprises at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100 or more ATs per L. When a single ligand is linked to multiple AT's, the AT's can each be linked to the ligand via a single linker or via a plurality of linkers (e.g., one linker per AT).
  • Examples of ligands contemplated in the methods herein include ligands that selectively bind cell surface marker(s) (e.g., receptors and adhesion molecules) of rare cells of interest. A ligand can comprise molecule(s), peptide(s), polypeptides, particles, and the like, and/or fragments thereof. The ligand can be naturally occurring or artificially synthesized. Rare cells include circulating tumor cells (CTCs), circulating epithelial cells or circulating stem cells.
  • In some embodiments, a ligand comprises an antibody, such as a monoclonal antibody or a polyclonal antibody. Examples of ligand antibodies contemplated herein include antibodies that selectively bind CTCs, circulating epithelial cells, or circulating stem cells. In some embodiments, such antibodies selectively bind an antigen such as EpCam; E-Cadherin, Mucin-1, Cytokeratin (CK) 8, epidermal growth factor receptor (EGFR), cytokeratin (CK)19, ErbB2, PDGF, L6, or leukocyte associated receptor (LAR). In certain embodiments, the ligand may be an antibody to a marker listed in FIG. 3.
  • In other embodiments, a ligand is not an antibody. Examples of non-antibody ligands include folic acid, Dolichos Biflorus Agglutinin (DBA), epidermal growth factor (EGF), EGF peptide (amino acid sequence YHWYGYTPQNVI), epi peptide (amino acid sequence QMARIPKRLARH), transforming growth factor-alpha (TGF-alpha), Urokinase Plasminogen Activator (UPA), FasL, MUC1/sec, catenin, ICAM-1, plasminogen, or the like. In some embodiments, the ligand activates a cellular process, and in other embodiments, the ligand may not activate a cellular process.
  • An ATL may have a single ligand or multiple ligands (e.g., x>1, or x>2, 5, 10, 20, or more). When an ATL comprises multiple ligands, each ligand may be identical to the other ligands, different from the other ligands, or a combination thereof.
  • Affinity tags (AT) can include molecules, peptides, polypeptides, particles, and/or other substances capable of being captured by a capture moiety or enrichment device. Examples of ATs include biotin, desthiobiotin, histidine, poly-histidine, glutathione S transferase (GST), myc, hemagglutinin (HA), FLAG, fluorescence tag, tandem affinity purification (TAP) tags, or derivatives thereof. The TAP tag may comprise calmodulin-binding protein, TEV, and protein A or G subunit. In some embodiments, the affinity tag comprises a magnetic particle. In other embodiments, the affinity tag is a molecule or particle other than a magnetic particle. In some instances, an affinity tag does not comprise an antibody.
  • As described above, an ATL may comprise one AT, or, for example, may comprise at least 2, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or more ATs.
  • To detect rare analytes (or single analyte) in a fluid sample, the sample is mixed with a homogenous or heterogeneous set of ATLs. The sample is incubated with the ATLs for a sufficient amount of time to enable binding of the ligands to the receptors or rare analytes. The sample and ATLs are then applied to one or more capture moieties that selectively bind the affinity tags, thereby allowing enrichment of the bound rare analytes. The capture moiety can be coupled to a solid support (e.g. a tube, a flat substrate, or an array of obstacles).
  • To detect rare analytes in a solid or semi-solid sample, the sample is first solubilized and then mixed with the mixture of ATLs as described above. Once the sample is incubated with the ATLs for a sufficient period of time to allow binding between the ligands and the rare analyte markers, the sample is applied to one or more capture moieties that selectively binds to the affinity tag.
  • Capture moieties may be inorganic molecules, organic molecules, peptides, polypeptides, and/or antibodies, and the like, or may include fragments of, or derivatives, of same. The capture moieties are capable of binding to, or interacting with, an affinity tag. Examples of capture moieties include, but are not limited to, a magnet or magnetized substrate, avidin, streptavidin, Neutravidin™, glutathione, nickel, calcium/calmodulin, or IgG. Other examples of capture moieties include magnetic or magnetized surfaces, avidin and avidin-coated particles.
  • In some instances, capture moieties are part of a microfluidic device (e.g., a microfluidic gap or channel coated with capture moieties). A microfluidic device contemplated herein can comprise an array of obstacles that form a network of microfluidic channels.
  • The affinity tags can bind irreversibly or reversibly to the capture moiety(ies). In some instances, an affinity tag may be releasable from the capture moiety. For example, desthio-biotin may be used as an affinity tag with avidin as the capture moiety. The bond between biotin and avidin can then be released by applying desphio-biotin or biotin to the sample.
  • In one example, the ATL's herein can be used to enrich rare analytes such as cells from a mixed sample such as blood. Such method comprises the step of contacting in solution a test sample with affinity-tagged ligands (ATLs). Each ATL comprises: at least one ligand linked to at least one affinity tag. The ligand and affinity tag are optionally liked via a linker comprising one or more of modified dextran, polyethylene glycol, polypropylene glycol, polyvinyl alcohol, or polyvinylpyrrolidone.
  • The ligands of the ATL's selectively bind a one or more markers of the rare analytes. The affinity tags of the ATLs are ones that can be selectively captured by a single capture moiety or a plurality of capture moieties. Examples of capture moieties contemplated for any of the embodiments herein include avidin, streptavidin, Neutravidin™, nickel, or glutathione. The affinity tags may be one that does not comprise a magnetic particle. Examples of affinity tags include biotin, desthiobiotin, histidine, polyhistidine, myc, hemagglutinin (HA), FLAG, fluorescence tag, tandem affinity purification (TAP) tags, FLAG, glutathione S transferase (GST) or derivatives thereof. After incubation for a sufficient amount of time to allow the sample and ATL's to mix, the mixed sample is contacted with one or more capture moieties or is flowed through a microfluidic device comprising the one or more capture moieties. This selectively retains ATL-bound analytes or cells.
  • In some instances, each ATL comprises a ratio of ligand to affinity tag such that there are more affinity tags for each ligand. In some instances the ligand:affinity tag ratio is less than 1:1 or less than 1:5 or less than 1:10 or less than 1:100. Furthermore, a single ATL can have at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 different ligands. Each of the ligands can be specific to a different marker, such as a cancer marker.
  • Cellular cancer markers contemplated herein include markers for a cancer such as breast, prostate, liver, ovary, skin, colon, rectum, cervix, esophagus, stomach, brain, lung, pancreatic, or endometrium cancer. In some instances a cellular marker is epidermal growth factor receptor (EGFR), EPCAM, or folic acid receptor. In some instances, the cellular marker is E-Cadherin, Mucin-1, Cytokeratin (CK) 8, cytokeratin (CK)19, ErbB2, PDGF, L6, or leukocyte associated receptor (LAR) In other instances it is any marker listed in the table of FIG. 3.
  • To enrich rare analytes such as rare cells (epithelial cells or CTC) found in bodily fluid (e.g., blood), the ligands in the ATL's can be one or more of the following: folic acid, epidermal growth factor (EGF), transforming growth factor-alpha (TGF-alpha), Urokinase Plasminogen Activator (UPA), FasL, MUC1/sec, catenin, ICAM-1, plasminogen, or fragments thereof. In some embodiments, the ligands comprise haptens. In some instances, the ligand is an antibody and in others it is not an antibody.
  • In some instances, a reagent used to enrich/detect rare analytes comprises a plurality of affinity-tagged ligands (ATLs) wherein each ATL comprises: a first ATL comprising a first ligand that selectively binds a first marker of the rare analytes linked to a first affinity tag that is selectively captured by a first capture moiety; and a second ATL comprising a second ligand that selectively binds a second marker linked to a second affinity tag, wherein the second affinity tag is selectively captured by the first capture moiety. In such embodiments, the reagent described above is mixed with a mixed sample of analytes. After allowing the ATL's and sample to mix for a sufficient amount of time for binding to occur, the sample/ATL mixture is contacted with the first capture moiety to selectively enrich the rare analytes. The capture moiety can be avidin and the capture moiety can be in a microfluidic gap or channel. The first and second affinity tags can be identical (both biotin) or different (biotin and desphio-biotin) but both selectively captured by the same capture moiety. In some instances, a mixed sample such as the one described above is contacted with at least 3, 4, 5, 6, 7, 8, 9, or 10 different ATL's each of which comprises an affinity tag that can be selectively captured by a single capture moiety or the same affinity tag.
  • A sample, such as a blood sample, can be mixed with one or more different ATLs. In certain embodiments, ATLs of similar configuration may be contacted with the targeted analytes. In other embodiments, a mixture of different ATLs may be used. In still other embodiments, step-wise purification of the analyte may occur through sequential use of the same or different ATLs.
  • An exemplary ATL can have a single ligand comprising anti-EpCAM antibody linked to a plurality of ATs, each of which comprises a biotin molecule. The ATs are linked to the ligand via a branched linker such that each ligand is coupled to at least five ATs. In some embodiments, the ligand may bind the marker (EpCAM) at more than one site. In other embodiments, e.g., EGF, the ligand binds the marker only once. Once the sample is mixed with the ATLs, the sample flows through a microfluidic device, optionally comprising an array of obstacles, coated with avidin capture moieties. Enriched rare cells (e.g., circulating epithelial cells) can then be visualized/detected using any means known in the art, including fluorescent in situ hybridization (FISH) staining.
  • Some applications may require analysis downstream of the capture of the ATL-bound cells. In some embodiments, the ATLs may be conjugated to one or more detectable labels. Such detectable labels comprise fluorescent markers, HRP-alkaline phosphatase detection or quantum dots. In some embodiments, in addition to an ATL, the cells may be contacted with a detectably-labeled ligand specific for a cellular marker. Such detectable labels may comprise one or more of fluorescent probes, magnetic particles, or quantum dots. The detectably-labeled ligands comprise the ligands described herein relating to ATLs. An example of a detectably-labeled ligand is a fluorescently-labeled antibody.
  • Varying the number of affinity tags and/or ligands in a single ATL may affect the ability to capture target analytes. Thus, the disclosure provides ATLs with more than one affinity tag and/or more than one ligand. The affinity tags may be identical tags, similar tags, or different tags. Since higher affinity-tag-to-ligand ratios may result in enhanced or more efficient capture of cells, the ratio of affinity tag to ligand in a single ATL may be greater than or equal to 1, for example, 2:1, 3:1, 4:1, 5:1, 10:1, 20:1, or greater.
  • In some embodiments, the marker is a marker for one or more of the following: cancer of the breast, lung, prostate, liver, ovary, skin, colon, rectum, cervix, esophagus, stomach, brain, bladder, kidney, testicular, or endometrium. In some embodiments, the marker is for a blood cancer such as leukemia or lymphoma.
  • In some embodiments, vascular disease is monitored by enriching for cells with endothelial markers. Other cancers may also be monitored by enriching for endothelial cells. In some embodiments, fetal markers (e.g. Y chromosome proteins, gamma globin) are used for capturing fetal cells in the maternal circulation. In some embodiments, stem cell markers (CD44) are used to capture stem cells.
  • In certain embodiments, the methods provided comprise contacting a cellular sample with one or more ATLs to enable binding to one or more cellular markers, followed by capture of the bound cells by an enrichment device. The contacting of the cellular sample with one or more ATLs may occur under conditions pre-determined to maximize binding efficiency. In some embodiments, the conditions may be optimized to minimize non-specific binding. For example, the timing of the contacting between the cellular sample and the one or more ATLs may be optimized. Such optimized or predetermined amount of time may be used for the contacting step. Likewise, conditions for the temperature of the contacting step may be optimized to maximize binding efficiency and/or to minimize internalization of cellular markers. A pre-determined or optimized temperature or temperatures may be used for the contacting step. In some embodiments, the composition of the solution containing the cellular sample and/or the ATL may be optimized for more efficient binding. Blocking reagents or serums may be added to aid in binding efficiency. Examples of such blocking reagents include bovine serum albumin (BSA), fetal calf serum (FCS), milk, and other commercially-obtainable reagents.
  • The methods may further comprise a wash step in which unbound (or free) ATL is removed from the cellular sample prior to capture by the enrichment device. For example, the wash step could be accomplished by one or more rounds comprising centrifugation of the cellular sample, aspiration of the supernatant, and re-suspension of the cellular sample in wash buffer. The composition of the wash buffer may comprise buffered solutions and may be optimized to maximize binding efficiency. The optimized wash buffer may comprise one or more blocking reagents or serums described herein.
  • In some embodiments, the cells are added to an enrichment device that comprises a surface functionalized with a capture moiety recognizing the affinity tag or a cellular marker, such as a receptor. In certain embodiments, a surface of the enrichment device is coated or treated with one or more capture moieties (e.g., avidin or Neutravidin) in order to allow capture of the ATL-bound cells. In certain embodiments, such capture-moieties are not antibodies. In some embodiments, such capture moieties are ligands. In some embodiments, the enrichment device comprises a surface coated or functionalized with a ligand that is used to directly enrich cells expressing a specific marker from a mixed cell population. In some embodiments, the surface of such enrichment device is functionalized with folate in order to enrich cells expressing the folate receptor. In some embodiments, the enrichment device is functionalized with Dolichos Biflorus Agglutinin (DBA), epidermal growth factor (EGF), EGF peptide (amino acid sequence YHWYGYTPQNVI), epi peptide (amino acid sequence QMARIPKRLARH), transforming growth factor-alpha (TGF-alpha), Urokinase Plasminogen Activator (UPA), FasL, MUC1/sec, catenin, ICAM-1, plasminogen, or the like. Parameters such as timing, temperature, and/or buffer composition may be optimized to promote optimal capture by the enrichment device.
  • The enrichment device may include one or more arrays of obstacles that allow lateral displacement of cells and other components of fluids. Such arrays of obstacles comprise different configurations. In one configuration, a row or rows of obstacles are arranged with a 50% offset from other randomly- or non-randomly-arranged obstacles creating restricted and expanded gaps.
  • In some embodiments, the obstacles within the array of obstacles are coated or treated with one or more capture moieties or ligands. In some embodiments, the enrichment device is capable of sorting cells based on another variable, e.g. hydrodynamic size, as well as capturing ATL-bound cells. Enrichment devices include, but are not limited to centrifuge, microfuge and ultracentrifuge test tubes. In some embodiments, the enrichment device is a column or other such receptacle such as a magnetic activated cell sorting (MACS) column.
  • Any of the ATLs herein may be designed to enrich cancer cells as well as prognose and diagnose cancer conditions. For example, cancer can be staged or diagnosed by enriching rare cells (e.g., epithelial cells, circulating cancer stem cells) using ATL's by any of the means described above. Subsequently, the enriched cells can be further evaluated or quantified. In one instance, diagnosis or prognoses comprises comparing the percentage or quantity of epithelial cells in the blood of a test subject with that in the blood of a healthy control subject, a panel of healthy control subjects, known standard levels, or similar information obtained from the same patient at a different point in time.
  • Peptide Library
  • In some embodiments, the present disclosure provides a method for screening a combinatorial peptide library for peptide ligands capable of binding cell surface markers. Such methods comprise contacting a sample of cancer cells with a combinatorial peptide library, wherein the peptides have been pre-labeled with one or more affinity tags, described herein; purifying out the cells selectively binding to candidate peptide ligands; and identifying the candidate ligands bound to the cells. In certain embodiments, the purifying may comprise the lateral flow of the cellular sample through a device coated with capture moieties that selectively bind the ATs so as to permit capture of the ATL bound cells
  • EXAMPLES Example 1 Capture of H1650 Lung Cancer Cells with Biotinylated Anti-EpCam Antibody
  • The example depicted in FIG. 1 illustrates a method and device for isolating cancer cells. The affinity-tagged ligand (ATL) in this example comprised biotin as the affinity tag. The ligand was anti-Epithelial Cell Adhesion Molecule (EpCam) antibody which recognizes an epithelial cellular marker. For the experiment, H1650 lung cancer cells were incubated with biotinylated goat anti-EpCam antibody for 1 hour on ice (FIG. 1B). Approximately 1000 cells were input into each experiment. The left and right images represent replicate experiments. As a negative control, H1650 lung cancer cells were incubated with biotinylated goat IgG antibody under the same or similar conditions (FIG. 1A). Following the incubation, the cells were washed and run through an array of obstacles [comprising a restricted gap—Chip 7, please confirm] chip coated with Neutravidin™. Cells were then fixed and visualized by fluorescence microscopy.
  • The results of this experiment demonstrated that it is possible to use ATLs to isolate cancer cells. In this example, between 20 and 30% of the total H1650 lung cancer cell population were recovered when anti-EpCam antibody was used as the ligand. To calculate the percentage (%), the # of cells captured was divided by the total # of cells passed onto the chip, and the resulting value was multiplied by 100. In contrast, only 7-8% of cells were recovered when the goat IgG was used.
  • Example 2 Capture of Cells after Solution Phase Binding of the Cells with an Affinity-Tagged Ligand
  • The examples depicted in FIG. 2 illustrate the capture of cells labeled with an affinity tag before being subjected to a microfluidic device. FIG. 2A is a diagram depicting a cell being contacted with an affinity-tagged ligand in solution (top panel) and the capture of such cell with a microfluidic device coated with a capture moiety capable of recognizing the affinity-tag (lower panel).
  • FIG. 2B illustrates the capture of cells bound to EGF peptide tagged with biotin. In this example, MDA-MB-231 cells (a breast cell line which expresses low levels of EpCam) were contacted with biotin-tagged EGF peptide in solution under conditions favorable for binding. The cells were then subjected to a chip coated with neutravidin, a capture moiety capable of recognizing the affinity tag. Following fixation, the captured cells were visualized by fluorescent microscopy. The results demonstrate significant capture of cells using this method.

Claims (12)

1. A method for enriching rare analytes from a sample comprising:
contacting in solution said sample with a plurality of affinity-tagged ligands (ATLs) wherein said mixture of ATL's comprises:
a first ATL comprising a first ligand that selectively binds a first marker of said rare analytes, wherein said first ligand is linked to a first affinity tag that is selectively captured by a first capture moiety; and
a second ATL comprising a second ligand that selectively binds a second marker of said rare analytes, wherein said second ligand is linked to a second affinity tag, wherein said second affinity tag is selectively captured by said first capture moiety; and
contacting said sample with said capture moiety to selectively enrich said rare analytes.
2. The method of claim 11, wherein said first affinity tag and said second affinity tag are identical.
3. The method of claim 11, wherein said mixture of ATL's comprises at least 3, 4, 5, 6, 7, 8, 9, or 10 ATL's each of which comprises an affinity tag that can be selectively captured by the first capture moiety.
4. The method of claim 11, wherein said analytes are cells and said mixture is a blood sample.
5. The method of claim 1, 2, or 3 wherein each of said ATL's comprises a ratio of Ligand:Affinity Tag that is less than 1:5.
6. The method of claim 15, wherein said capture moiety is in a microfluidic device.
7. The method of claim 16, wherein said microfluidic device comprises an array of obstacles.
8. The method of claim 1, 2, or 3 wherein said affinity tag comprises biotin, desthiobiotin, histidine, polyhistidine, myc, hemagglutinin (HA), FLAG, fluorescence tag, tandem affinity purification (TAP) tags, FLAG, glutathione S transferase (GST) or derivatives thereof.
9. The method of claim 1, 2, or 3, wherein said ligand is linked to said affinity tag via a linker comprising one or more of modified dextran, polyethylene glycol, polypropylene glycol, polyvinyl alcohol, and polyvinylpyrrolidone.
10. The method of claim 1 or 2 wherein the cellular marker is a cancer marker for one or more of breast, prostate, liver, ovary, skin, colon, rectum, cervix, esophagus, stomach, brain, lung, or endometrium cancer.
11. The method of claim 1, 2, or 3, wherein the ligand selectively binds epidermal growth factor receptor (EGFR) or folic acid receptor.
12. The method of claim 1, 2, or 3, wherein the capture moiety comprises avidin, streptavidin, Neutravidin™, nickel, or glutathione.
US13/182,003 2008-02-25 2011-07-13 Tagged Ligands for Enrichment of Rare Analytes from a Mixed Sample Abandoned US20110300603A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US13/182,003 US20110300603A1 (en) 2008-02-25 2011-07-13 Tagged Ligands for Enrichment of Rare Analytes from a Mixed Sample
US13/692,710 US20130260392A1 (en) 2008-02-25 2012-12-03 Tagged ligands for enrichment of rare analytes from a mixed sample
US14/103,352 US20140234986A1 (en) 2008-02-25 2013-12-11 Tagged ligands for enrichment of rare analytes from a mixed sample
US14/995,894 US10359429B2 (en) 2008-02-25 2016-01-14 Tagged ligands for enrichment of rare analytes from a mixed sample

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/037,077 US8008032B2 (en) 2008-02-25 2008-02-25 Tagged ligands for enrichment of rare analytes from a mixed sample
US13/182,003 US20110300603A1 (en) 2008-02-25 2011-07-13 Tagged Ligands for Enrichment of Rare Analytes from a Mixed Sample

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/037,077 Division US8008032B2 (en) 2008-02-25 2008-02-25 Tagged ligands for enrichment of rare analytes from a mixed sample

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/692,710 Continuation US20130260392A1 (en) 2008-02-25 2012-12-03 Tagged ligands for enrichment of rare analytes from a mixed sample

Publications (1)

Publication Number Publication Date
US20110300603A1 true US20110300603A1 (en) 2011-12-08

Family

ID=40998689

Family Applications (5)

Application Number Title Priority Date Filing Date
US12/037,077 Expired - Fee Related US8008032B2 (en) 2008-02-25 2008-02-25 Tagged ligands for enrichment of rare analytes from a mixed sample
US13/182,003 Abandoned US20110300603A1 (en) 2008-02-25 2011-07-13 Tagged Ligands for Enrichment of Rare Analytes from a Mixed Sample
US13/692,710 Abandoned US20130260392A1 (en) 2008-02-25 2012-12-03 Tagged ligands for enrichment of rare analytes from a mixed sample
US14/103,352 Abandoned US20140234986A1 (en) 2008-02-25 2013-12-11 Tagged ligands for enrichment of rare analytes from a mixed sample
US14/995,894 Expired - Lifetime US10359429B2 (en) 2008-02-25 2016-01-14 Tagged ligands for enrichment of rare analytes from a mixed sample

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/037,077 Expired - Fee Related US8008032B2 (en) 2008-02-25 2008-02-25 Tagged ligands for enrichment of rare analytes from a mixed sample

Family Applications After (3)

Application Number Title Priority Date Filing Date
US13/692,710 Abandoned US20130260392A1 (en) 2008-02-25 2012-12-03 Tagged ligands for enrichment of rare analytes from a mixed sample
US14/103,352 Abandoned US20140234986A1 (en) 2008-02-25 2013-12-11 Tagged ligands for enrichment of rare analytes from a mixed sample
US14/995,894 Expired - Lifetime US10359429B2 (en) 2008-02-25 2016-01-14 Tagged ligands for enrichment of rare analytes from a mixed sample

Country Status (1)

Country Link
US (5) US8008032B2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9541480B2 (en) 2011-06-29 2017-01-10 Academia Sinica Capture, purification, and release of biological substances using a surface coating
US10107726B2 (en) 2016-03-16 2018-10-23 Cellmax, Ltd. Collection of suspended cells using a transferable membrane
US10112198B2 (en) 2014-08-26 2018-10-30 Academia Sinica Collector architecture layout design
US10359429B2 (en) 2008-02-25 2019-07-23 Gpb Scientific, Llc Tagged ligands for enrichment of rare analytes from a mixed sample
US10495644B2 (en) 2014-04-01 2019-12-03 Academia Sinica Methods and systems for cancer diagnosis and prognosis

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8921121B2 (en) * 2007-06-29 2014-12-30 The Trustees Of Columbia University In The City Of New York Methods, devices, and systems for chemiluminescence-based microfluidic cell counting
US8431090B2 (en) 2007-06-29 2013-04-30 The Trustees Of Columbia University In The City Of New York Microfluidic device for counting biological particles
US20120100538A1 (en) * 2009-03-24 2012-04-26 Biocept, Inc. Devices and methods of cell capture and analysis
CA2756493C (en) * 2009-03-24 2019-07-02 Biocept, Inc. Devices and methods of cell capture and analysis
US8790916B2 (en) 2009-05-14 2014-07-29 Genestream, Inc. Microfluidic method and system for isolating particles from biological fluid
WO2011057347A1 (en) 2009-11-12 2011-05-19 Tgr Biosciences Pty Ltd Analyte detection
US9034658B2 (en) * 2009-11-23 2015-05-19 The General Hospital Corporation Microfluidic devices for the capture of biological sample components
CA2786470A1 (en) * 2010-01-12 2011-07-21 Ayelet David Targeted delivery systems for diagnostic applications
KR101519379B1 (en) * 2010-04-29 2015-05-12 삼성전자 주식회사 Centrifugal Micro-fluidic Device and Method for immunoassay
EP2786148A4 (en) * 2011-03-31 2015-12-16 Tgr Biosciences Pty Ltd One-step immunoassay detection of analytes
CA2842359A1 (en) 2011-08-01 2013-02-07 Denovo Sciences Cell capture system and method of use
US10466160B2 (en) 2011-08-01 2019-11-05 Celsee Diagnostics, Inc. System and method for retrieving and analyzing particles
US9174216B2 (en) 2013-03-13 2015-11-03 DeNovo Science, Inc. System for capturing and analyzing cells
US9404864B2 (en) 2013-03-13 2016-08-02 Denovo Sciences, Inc. System for imaging captured cells
EA201492284A1 (en) 2012-06-27 2015-11-30 Берг Ллк APPLICATION OF MARKERS IN DIAGNOSTICS AND TREATMENT OF PROSTATE CANCER
US9606102B2 (en) 2013-01-26 2017-03-28 Denovo Sciences, Inc. System and method for capturing and analyzing cells
US9707562B2 (en) 2013-03-13 2017-07-18 Denovo Sciences, Inc. System for capturing and analyzing cells
CN113512522A (en) 2013-03-15 2021-10-19 普林斯顿大学理事会 Method and apparatus for high throughput purification
US20150064153A1 (en) 2013-03-15 2015-03-05 The Trustees Of Princeton University High efficiency microfluidic purification of stem cells to improve transplants
EP2971287B1 (en) 2013-03-15 2019-08-14 GPB Scientific, LLC On-chip microfluidic processing of particles
US10391490B2 (en) 2013-05-31 2019-08-27 Celsee Diagnostics, Inc. System and method for isolating and analyzing cells
US9856535B2 (en) 2013-05-31 2018-01-02 Denovo Sciences, Inc. System for isolating cells
CN106662584B (en) * 2014-04-30 2020-05-05 Iba股份有限公司 Method for isolating target cells
EP3230314B1 (en) 2014-12-08 2023-05-03 Berg LLC Use of markers including filamin a in the diagnosis and treatment of prostate cancer
WO2016136273A1 (en) * 2015-02-27 2016-09-01 凸版印刷株式会社 Method for separating cells, and device therefor
US10976232B2 (en) 2015-08-24 2021-04-13 Gpb Scientific, Inc. Methods and devices for multi-step cell purification and concentration
EP3373822A1 (en) * 2015-11-11 2018-09-19 Medizinische Universität Graz In vivo collection and localized quantification and profiling of circulating cells, proteins and nucleic acids
US20170370925A1 (en) * 2016-06-27 2017-12-28 Tgr Biosciences Pty Ltd. Lateral Flow Analyte Detection
US10972456B2 (en) * 2016-11-04 2021-04-06 Microsoft Technology Licensing, Llc IoT device authentication
US10391492B2 (en) 2017-08-29 2019-08-27 Celsee Diagnostics, Inc. System and method for isolating and analyzing cells
EP3675876A4 (en) 2017-09-01 2021-06-02 GPB Scientific, Inc. Methods for preparing therapeutically active cells using microfluidics
CN109856388A (en) * 2018-11-29 2019-06-07 北京优迅医学检验实验室有限公司 The catching method and capture kit of circulating tumor cell
US10633693B1 (en) 2019-04-16 2020-04-28 Celsee Diagnostics, Inc. System and method for leakage control in a particle capture system
US11273439B2 (en) 2019-05-07 2022-03-15 Bio-Rad Laboratories, Inc. System and method for target material retrieval from microwells
SG11202112151UA (en) 2019-05-07 2021-12-30 Bio Rad Laboratories System and method for automated single cell processing
WO2020251802A1 (en) 2019-06-14 2020-12-17 Bio-Rad Laboratories, Inc. System and method for automated single cell processing and analyses
US11504719B2 (en) 2020-03-12 2022-11-22 Bio-Rad Laboratories, Inc. System and method for receiving and delivering a fluid for sample processing
CN111410690B (en) * 2020-04-09 2021-08-06 福州迈新生物技术开发有限公司 anti-CK 19 protein monoclonal antibody, cell line, preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080124721A1 (en) * 2006-06-14 2008-05-29 Martin Fuchs Analysis of rare cell-enriched samples

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385707A (en) 1988-12-28 1995-01-31 Stefan Miltenyi Metal matrices for use in high gradient magnetic separation of biological materials and method for coating the same
US6156270A (en) 1992-05-21 2000-12-05 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US7166423B1 (en) 1992-10-21 2007-01-23 Miltenyi Biotec Gmbh Direct selection of cells by secretion product
US5427663A (en) 1993-06-08 1995-06-27 British Technology Group Usa Inc. Microlithographic array for macromolecule and cell fractionation
US5707799A (en) 1994-09-30 1998-01-13 Abbott Laboratories Devices and methods utilizing arrays of structures for analyte capture
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
US5715946A (en) 1995-06-07 1998-02-10 Reichenbach; Steven H. Method and apparatus for sorting particles suspended in a fluid
US6190870B1 (en) 1995-08-28 2001-02-20 Amcell Corporation Efficient enrichment and detection of disseminated tumor cells
ATE236386T1 (en) 1995-11-30 2003-04-15 Chromavision Med Sys Inc METHOD FOR AUTOMATIC IMAGE ANALYSIS OF BIOLOGICAL SAMPLES
US6718053B1 (en) 1996-11-27 2004-04-06 Chromavision Medical Systems, Inc. Method and apparatus for automated image analysis of biological specimens
US5837116A (en) * 1996-07-12 1998-11-17 California Institute Of Technology Two dimensional electrophoresis apparatus
US6074827A (en) 1996-07-30 2000-06-13 Aclara Biosciences, Inc. Microfluidic method for nucleic acid purification and processing
CA2320418C (en) 1998-02-12 2008-06-17 Leon W.M.M. Terstappen Methods and reagents for the rapid and efficient isolation of circulating cancer cells
ES2279600T3 (en) 1998-03-12 2007-08-16 Miltenyi Biotec Gmbh MICROCOLUMN SYSTEM FOR MAGNETIC SEPARATION.
US6613581B1 (en) 1999-08-26 2003-09-02 Caliper Technologies Corp. Microfluidic analytic detection assays, devices, and integrated systems
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
EP1309863A1 (en) 2000-08-08 2003-05-14 Aviva Biosciences Corporation Methods for manipulating moieties in microfluidic systems
US20040005582A1 (en) 2000-08-10 2004-01-08 Nanobiodynamics, Incorporated Biospecific desorption microflow systems and methods for studying biospecific interactions and their modulators
AU8843701A (en) 2000-09-09 2002-03-22 Univ New York State Res Found Method and compositions for isolating metastatic cancer cells, and use in measuring metastatic potential of a cancer thereof
US6913697B2 (en) 2001-02-14 2005-07-05 Science & Technology Corporation @ Unm Nanostructured separation and analysis devices for biological membranes
US6685841B2 (en) 2001-02-14 2004-02-03 Gabriel P. Lopez Nanostructured devices for separation and analysis
US8980568B2 (en) 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
US7262269B2 (en) 2001-10-26 2007-08-28 The Regents Of University Of California Method for screening combinational bead library; ligands for cancer cells
AU2003216175A1 (en) 2002-02-04 2003-09-02 Colorado School Of Mines Laminar flow-based separations of colloidal and cellular particles
WO2003069421A2 (en) 2002-02-14 2003-08-21 Immunivest Corporation Methods and algorithms for cell enumeration in a low-cost cytometer
WO2003085379A2 (en) 2002-04-01 2003-10-16 Fluidigm Corporation Microfluidic particle-analysis systems
US7217562B2 (en) 2002-04-16 2007-05-15 Princeton University Gradient structures interfacing microfluidics and nanofluidics, methods for fabrication and uses thereof
US20040018611A1 (en) 2002-07-23 2004-01-29 Ward Michael Dennis Microfluidic devices for high gradient magnetic separation
JP4142922B2 (en) 2002-09-12 2008-09-03 株式会社ルネサステクノロジ Strobe control circuit, IGBT device, semiconductor device and electronic equipment
ES2375724T3 (en) 2002-09-27 2012-03-05 The General Hospital Corporation MICROFLUDE DEVICE FOR SEPERATION OF CELLS AND ITS USES.
ES2341103T3 (en) 2002-10-23 2010-06-15 The Trustees Of Princeton University CONTINUOUS SEPARATION PROCEDURE OF PARTICLES USING RETICULATES OF ASYMETRICALLY ALIGNED OBSTACLES REGARDING FIELDS.
US7122384B2 (en) 2002-11-06 2006-10-17 E. I. Du Pont De Nemours And Company Resonant light scattering microparticle methods
JP2004263719A (en) 2003-02-05 2004-09-24 Hitachi Sumitomo Heavy Industries Construction Crane Co Ltd Negative braking device, construction machine, and negative braking method
WO2004077021A2 (en) 2003-02-27 2004-09-10 Lesko Stephen A Standardized evaluation of therapeutic efficacy based on cellular biomarkers
JP4593557B2 (en) 2003-02-27 2010-12-08 ベリデックス・リミテッド・ライアビリティ・カンパニー Circulating tumor cells (CTC): early assessment of time to progression, survival and response to therapy in patients with metastatic cancer
US20070160503A1 (en) 2003-06-13 2007-07-12 Palaniappan Sethu Microfluidic systems for size based removal of red blood cells and platelets from blood
US20050266433A1 (en) 2004-03-03 2005-12-01 Ravi Kapur Magnetic device for isolation of cells and biomolecules in a microfluidic environment
US20090136982A1 (en) 2005-01-18 2009-05-28 Biocept, Inc. Cell separation using microchannel having patterned posts
US20060252087A1 (en) 2005-01-18 2006-11-09 Biocept, Inc. Recovery of rare cells using a microchannel apparatus with patterned posts
US20070026414A1 (en) * 2005-07-29 2007-02-01 Martin Fuchs Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20060223178A1 (en) 2005-04-05 2006-10-05 Tom Barber Devices and methods for magnetic enrichment of cells and other particles
US20070196820A1 (en) 2005-04-05 2007-08-23 Ravi Kapur Devices and methods for enrichment and alteration of cells and other particles
US20070026417A1 (en) 2005-07-29 2007-02-01 Martin Fuchs Devices and methods for enrichment and alteration of circulating tumor cells and other particles
EP1874920A4 (en) 2005-04-05 2009-11-04 Cellpoint Diagnostics Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US8354075B1 (en) 2005-04-21 2013-01-15 California Institute Of Technology Streamline-based microfluidic device
US20060266692A1 (en) 2005-05-25 2006-11-30 Innovative Micro Technology Microfabricated cross flow filter and method of manufacture
SE528233C2 (en) 2005-06-20 2006-09-26 Aamic Ab Fluid handling device for handling fluid to be assayed, comprises absorbing zone(s) in fluid contact with second end of first passage and comprising projections perpendicular to substrate surface and capable of generating capillary flow
US20070059680A1 (en) 2005-09-15 2007-03-15 Ravi Kapur System for cell enrichment
US7695956B2 (en) 2006-01-12 2010-04-13 Biocept, Inc. Device for cell separation and analysis and method of using
WO2007126938A2 (en) 2006-03-30 2007-11-08 Albert Einstein College Of Medicine Of Yeshiva University Marker for chromosomal abnormalities
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
GB0616045D0 (en) 2006-08-11 2006-09-20 Univ Bristol Blood cell separation
US8008032B2 (en) * 2008-02-25 2011-08-30 Cellective Dx Corporation Tagged ligands for enrichment of rare analytes from a mixed sample
EP3196642A1 (en) 2008-07-24 2017-07-26 The Trustees of Princeton University Bump array device having asymmetric gaps for segregation of particles
US8343440B2 (en) 2009-03-27 2013-01-01 Seiko Epson Corporation Cell separating apparatus and cell separating method
EP2603793A4 (en) 2010-08-15 2014-03-19 Gpb Scientific Llc Microfluidic cell separation in the assay of blood
CN103889556A (en) 2011-01-06 2014-06-25 Gpb科学有限责任公司 Circulating tumor cell capture on a microfluidic chip incorporating both affinity and size
US20190366342A1 (en) 2016-10-24 2019-12-05 Gpb Scientific, Llc Deterministic lateral displacement in the preparation of cells and compositions for therapeutic uses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080124721A1 (en) * 2006-06-14 2008-05-29 Martin Fuchs Analysis of rare cell-enriched samples

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Aggarwal et al. A combinatorial approach to the selective capture of circulating malignant epithelial cells by peptide ligands, Biomaterials 26: 6077-6086 (2005). *
Kurihara et al. Imaging Brain Tumors by Targeting Peptide Radiopharmaceuticals through Blood-Brain Barrier, Cancer Research 59: 6159-6163. *
Nagrath et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology (Nature 450: (20/27): 1235-1238 (December 2007)). *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10359429B2 (en) 2008-02-25 2019-07-23 Gpb Scientific, Llc Tagged ligands for enrichment of rare analytes from a mixed sample
US9541480B2 (en) 2011-06-29 2017-01-10 Academia Sinica Capture, purification, and release of biological substances using a surface coating
US11674958B2 (en) 2011-06-29 2023-06-13 Academia Sinica Capture, purification, and release of biological substances using a surface coating
US10495644B2 (en) 2014-04-01 2019-12-03 Academia Sinica Methods and systems for cancer diagnosis and prognosis
US10112198B2 (en) 2014-08-26 2018-10-30 Academia Sinica Collector architecture layout design
US10107726B2 (en) 2016-03-16 2018-10-23 Cellmax, Ltd. Collection of suspended cells using a transferable membrane
US10605708B2 (en) 2016-03-16 2020-03-31 Cellmax, Ltd Collection of suspended cells using a transferable membrane

Also Published As

Publication number Publication date
US10359429B2 (en) 2019-07-23
US20130260392A1 (en) 2013-10-03
US8008032B2 (en) 2011-08-30
US20090215088A1 (en) 2009-08-27
US20170023578A1 (en) 2017-01-26
US20140234986A1 (en) 2014-08-21

Similar Documents

Publication Publication Date Title
US10359429B2 (en) Tagged ligands for enrichment of rare analytes from a mixed sample
US10527622B2 (en) Antibody-based arrays for detecting multiple signal transducers in rare circulating cells
JP5722298B2 (en) Antibody-based arrays for detection of diverse signaling substances in rare circulating cells
DK2551672T3 (en) ANTIBODY-BASED arrays FOR DETECTION OF MULTIPLE signal transducers IN RARE CIRCULATING CELLS
US11320432B2 (en) System with buffer for lateral flow on a porous membrane
EP2460874B1 (en) Method of separating target cell in biological sample
WO2024001798A1 (en) Nucleic acid aptamer-based extracellular vesicle fluorescence polarization detection method and application thereof
GB2591009A (en) Composite target-tumor serum nucleic acid ligand detection method and kit
US20060172345A1 (en) Method for detecting low levels of a fusion protein
US20120225422A1 (en) Method and device employing a non-receptor ligand interaction with nanoparticles or other solid phase followed by specific detection
AU2013202682B2 (en) Antibody-based arrays for detecting multiple signal transducers in rare circulating cells
US20080099346A1 (en) Liquid crystal sensor system
JPH08327629A (en) Pretreatment of specimen
Bearinger Detector and related, devices, methods and systems

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION